Frankfurt
11.06.26 | 13:20
0,402 Euro
-24,15 % -0,128
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Eli Lilly continues dealmaking roll with $1bn AlzeCure agreement | 3 | Pharmaceutical Technology | ||
| Mi | XFRA CAPITAL ADJUSTMENT INFORMATION - 10.06.2026 | 119 | Xetra Newsboard | Das Instrument AC6 SE0010133785 ALZECURE PHARMA AB EQUITY wird cum Kapitalmassnahme gehandelt am 10.06.2026 und ex Kapitalmassnahme am 11.06.2026 The instrument AC6 SE0010133785 ALZECURE PHARMA AB EQUITY... ► Artikel lesen | |
| Di | Lilly moves deeper into Alzheimer's research with AlzeCure licensing deal | 8 | FierceBiotech | ||
| ALZECURE PHARMA Aktie jetzt für 0€ handeln | |||||
| Di | Lilly, AlzeCure ink Alzheimer's drug deal worth more than $1B | 11 | Seeking Alpha | ||
| Di | 1-Milliarde-Deal: Alzheimer-Hammer: Lilly schickt Mini-Biotech um 553 % nach oben | 640 | wallstreetONLINE | © Foto: OpenAIEli Lilly setzt mit AlzeCure auf eine Alzheimer-Tablette - und lässt die Aktie des kleinen Biotechs um mehr als 550 Prozent explodieren.Eli Lilly hat mit AlzeCure Pharma einen Kooperations-... ► Artikel lesen | |
| Di | AlzeCure-Aktie explodiert um 301 % nach Alzheimer-Deal mit Eli Lilly | 18 | Investing.com Deutsch | ||
| Di | AlzeCure Pharma Enters Into A Collaboration And Out-Licensing Agreement With Lilly For Alzheimer's Project | 1.151 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / June 9, 2026 / AlzeCure Pharma AB (publ) ("AlzeCure")(STO:ALZCUR)(FRA:AC6), which develops small-molecule drug candidates for CNS diseases with a focus on Alzheimer's... ► Artikel lesen | |
| Fr | AlzeCure Pharma AB: AlzeCure Pharma carries out previously announced rights issue of approximately SEK 30.1 million and publishes information document | 175 | GlobeNewswire (Europe) | AlzeCure Pharma AB (publ) (FN STO: ALZCUR), which develops small molecule drug candidates for CNS disorders, with a focus on Alzheimer's disease and pain, has today resolved to proceed with the rights... ► Artikel lesen | |
| 26.05. | Notice To Annual General Meeting in AlzeCure Pharma AB | 406 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / May 26, 2026 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - The shareholders of AlzeCure Pharma AB, reg. no. 559094-8302 (the "Company") are hereby invited to attend the... ► Artikel lesen | |
| 19.05. | AlzeCure Pharma to Host Live Seminar on The Pain Project TrkA-NAM ACD137 with a Focus on Osteoarthritis and Neuropathic Pain | 356 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / May 19, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 13.05. | AlzeCure Pharma to Present at Redeye Investor Forum Online on May 21 | 248 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / May 13, 2026 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's... ► Artikel lesen | |
| 13.05. | AlzeCure Pharma to Present at ABG Investor Days on May 21 | 251 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / May 13, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 06.05. | AlzeCure Pharma: New scientific Article Published on TrkA-NAM ACD137 Against Osteoarthritic Pain | 352 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / May 6, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing on... ► Artikel lesen | |
| 05.05. | AlzeCure Pharma: AlzeCure Publishes its Interim Report for January - March 2026 | 346 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / May 5, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6) today announced that its interim report for the period January - March 2026 is now available on the company's... ► Artikel lesen | |
| 30.04. | AlzeCure Pharma: Adjusted Timeline for the Previously Communicated Rights Issue | 594 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / April 30, 2026 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a biotech company that develops candidate drugs for diseases affecting... ► Artikel lesen | |
| 29.04. | XFRA CAPITAL ADJUSTMENT INFORMATION - 29.04.2026 | 566 | Xetra Newsboard | Das Instrument FWR0 CA98873A1057 YUMY CANDY COMPANY INC. EQUITY wird cum Kapitalmassnahme gehandelt am 29.04.2026 und ex Kapitalmassnahme am 30.04.2026 The instrument FWR0 CA98873A1057 YUMY CANDY COMPANY... ► Artikel lesen | |
| 24.04. | AlzeCure Pharma Carries Out a Fully Secured Rights Issue of Approximately SEK 30.1 million | 205 | ACCESS Newswire | NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, WITHIN OR INTO THE RUSSIAN FEDERATION, BELARUS, AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND... ► Artikel lesen | |
| 20.04. | AlzeCure Pharma: Last Patient has Completed AlzeCure's Phase Ib Clinical Study with NeuroRestore ACD856 | 409 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / April 20, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 08.04. | AlzeCure Pharma Publishes its Annual Report for 2025 | 320 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / April 8, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 07.04. | AlzeCure Pharma to Present at Redeye Healthcare Day on April 14 | 328 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / April 7, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen |
1 2 3 Weiter >>
49 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VERTEX PHARMACEUTICALS | 380,40 | +0,78 % | Vertex Pharmaceuticals Incorporated: Vertex Presents New Data on CASGEVY, Including First European Presentation of Data in Children Ages 5-11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions | - Data from pivotal studies of CASGEVY in children ages 5-11 with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrate transformative potential in younger patients, consistent... ► Artikel lesen | |
| VIATRIS | 13,746 | +0,57 % | Dividendenbekanntmachungen (22.05.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) 3M COMPANY US88579Y1010 0,78 USD 0,6712 EUR ACCO BRANDS CORPORATION US00081T1088 0,075 USD 0,0645 EUR ADVANCED ENERGY INDUSTRIES... ► Artikel lesen | |
| ALTIMMUNE | 2,365 | +4,42 % | Is Altimmune Worth Buying Ahead of 2026 Catalysts? | ||
| SELLAS LIFE SCIENCES | 6,380 | +2,90 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update | - Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events - - First Patient Dosed in Phase 2 Trial of... ► Artikel lesen | |
| OPKO HEALTH | 1,220 | -3,17 % | OPKO Health, Inc.: OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results | MIAMI, April 28, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three months ended March 31, 2026. Highlights from the first... ► Artikel lesen | |
| JAGUAR HEALTH | 2,700 | -1,82 % | Jaguar Health, Inc.: Jaguar Health Reports Approval of All Proposals at 2026 Annual Meeting of Stockholders | Lisa Conte, Jaguar's founder, president & CEO, presenting virtually on June 10, 2026 at the Emerging Growth Conference; click here to register SAN FRANCISCO, CA / ACCESS Newswire / June 8, 2026 / Jaguar... ► Artikel lesen | |
| AURINIA PHARMACEUTICALS | 13,700 | +1,00 % | Aurinia Pharmaceuticals Inc. - 8-K, Current Report | ||
| KIORA PHARMACEUTICALS | 2,630 | 0,00 % | KIORA PHARMACEUTICALS INC - 8-K, Current Report | ||
| ACLARIS THERAPEUTICS | 3,600 | +1,18 % | Aclaris Therapeutics, Inc. (ACRS): A Top Penny Stock in Investors Portfolio That Stifel is Bullish On | ||
| LIPOCINE | 1,975 | -0,25 % | Lipocine Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| PHOTOCURE | 5,070 | -0,39 % | Photocure ASA to Acquire Vesica Health Inc., Strengthening Leadership in Bladder Cancer Diagnostics | OSLO, Norway, June 4, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), a leader in bladder cancer diagnostics, today announced the signing and successful completion... ► Artikel lesen | |
| EUROBIO SCIENTIFIC | 22,700 | +0,44 % | Eurobio scientific signs definitive agreement to acquire CareDx's transplant Lab Product division | EUROBIO SCIENTIFIC SIGNS DEFINITIVE AGREEMENT TO ACQUIRE CAREDX's TRANSPLANT LAB PRODUCT DIVISION Acquisition of CareDx's 'lab products' portfolio creates new opportunities for growth and innovation... ► Artikel lesen | |
| MEDICURE | 0,630 | 0,00 % | Medicure, Inc.: Medicure Announces AGM Results and Appointment of New Director | WINNIPEG, MB / ACCESS Newswire / May 21, 2026 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare... ► Artikel lesen | |
| BAYER | 36,150 | +2,21 % | Iran-Krieg: DAX schwächer - Broadcom, Crowdstrike, Hochtief, Porsche SE, RWE, Bayer, SAP im ... | Der DAX hat am Mittwoch deutlich Federn lassen müssen. Aus dem Handel ging er am Ende mit einem Minus von 1,3 Prozent bei 24.795,94 Zählern. Und auch der Start in den Donnerstag sieht schwächer aus.... ► Artikel lesen | |
| MERCK KGAA | 137,30 | +0,62 % | EQS-PVR: Merck KGaA: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Merck KGaA
Merck KGaA: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
08.06.2026 / 16:57 CET/CEST
Veröffentlichung... ► Artikel lesen |
ALZECURE PHARMA AB gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von -0,128 (-24,15 %) liegt der Kurs bei 0,402 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALZECURE PHARMA AB finden Sie auf Wallstreet Online.